5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity

Table of contents


This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.


Key facts

Medicine name
  • Xeloda
  • Capecitabine Accord
  • Capecitabine Medac
  • Capecitabine Teva
  • Ecansya (previously Capecitabine Krka)
  • Teysuno
Active substance
  • Fluorouracil
  • capecitabine
  • tegafur
Procedure number
Regulatory outcome
DHPC type
Referral - Article 31
Referral name
Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products
Human ATC code
  • L01BC06
  • L01BC53
  • L01BC02
Dissemination date

How useful was this page?

Add your rating